Kathryn Morris Gunnison, MD, MS
Addiction Medicine · San Jose
- Medicare standing
- 2 flags on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
- 1 Medical Board action on record
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Gunnison’s office at (408) 495-9471 to ask if they take your plan before you enroll.
California Medical Board record
Licence A124321 · Current
Licensed to practise in California · since 2013 · expires 2028-09-30 · Rosalind Franklin University, the Chicago Medical School. Board flags: Probation Completed.
Public record actions
| 2024-09-13 | Board disciplineDiscipline | Probation completed. · 8002023097208 |
Medicaid work
$181,956 in 2023
Medicaid paid $181,956 for 2,034 billed services this clinician did in 2023, up to 113 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 605 | $178,924 |
| Short return visit (20+ min) | 586 | $1,750 |
| Return visit (30+ min) | 158 | $746 |
| New patient visit (30+ min) | 83 | $398 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | 484 | $138 |
| Administration of patient-focused health risk assessment instrument (eg, health hazard appraisal) with scoring and documentation, per standardized instrument | 118 | $0 |
| 2023 | 2,034 | 6 | 113 | $181,956 |
| 2022 | 3,462 | 7 | 127 | $266,180 |
| 2021 | 2,832 | 7 | 98 | $223,208 |
See the largest Medicaid services in earlier years
2022
| Clinic visit/encounter, all-inclusive | 1,351 | $260,942 |
| Short return visit (20+ min) | 602 | $3,282 |
| Return visit (30+ min) | 774 | $1,403 |
| Long return visit (40+ min) | 137 | $394 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | 532 | $103 |
| New patient visit (30+ min) | 28 | $57 |
| Administration of patient-focused health risk assessment instrument (eg, health hazard appraisal) with scoring and documentation, per standardized instrument | 38 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 1,011 | $219,280 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 104 | $1,727 |
| Return visit (30+ min) | 414 | $875 |
| New patient visit (30+ min) | 76 | $594 |
| Short return visit (20+ min) | 476 | $337 |
| Long return visit (40+ min) | 55 | $325 |
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (eg, utilizing immunoassay [eg, dipsticks, cups, cards, or cartridges]), includes sample validation when performed, per date of service | 696 | $71 |
Drugs they prescribed that Part D paid
$2,806
Pharmacies billed $2,806 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 75) in 2024. At or below the middle of the specialty; the typical family medicine clinician is at 0%.
75 generic and 0 brand-name prescriptions · $2,806 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Naltrexone | 20 | $839 | $42 |
Year by year
| 2024 | 75 | 26 | 0% (0) | 0% | $2,806 |
| 2023 | 151 | 38 | 0% (0) | 26% | $43,556 |
| 2022 | 222 | 35 | 0% (0) | 27% | $54,993 |
| 2021 | 59 | 22 | 0% (0) | None | $6,718 |
| 2020 | 22 | 11 | 0% (0) | 0% | $767 |
| 2018 | 52 | 25 | 0% (0) | None | $4,236 |
| 2017 | 81 | 34 | 0% (0) | None | $7,068 |
| 2016 | 31 | 16 | None | None | $4,160 |
| 2015 | 20 | 14 | None | None | $941 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Suboxone | 33 | $24,076 | $730 |
| Buprenorphine-Naloxone | 32 | $8,311 | $260 |
| Acamprosate | 11 | $1,910 | $174 |
| Buprenorphine | 17 | $689 | $41 |
| Naltrexone | 15 | $597 | $40 |
2022: 5 drugs
| Suboxone | 60 | $39,307 | $655 |
| Buprenorphine-Naloxone | 70 | $11,801 | $169 |
| Acamprosate | 13 | $1,952 | $150 |
| Buprenorphine | 29 | $936 | $32 |
| Gabapentin | 12 | $84 | $7 |
2021: 1 drug
| Buprenorphine-Naloxone | 17 | $1,313 | $77 |
2017: 1 drug
| Hydrocortisone | 14 | $161 | $11 |
Money from drug and device companies
$43 in 2025
| 2025 | 2 | 2 | None | $43 |
| 2024 | 1 | 1 | None | $117 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
See all 2 published payments
| Braeburn | Meals · 2025-11-14 | Brixadi | $16 |
| Alkermes | Meals · 2025-03-19 | Vivitrol | $27 |
See earlier years (2024)
2024: $117
| ViiV Healthcare | Apretude | $117 | 1 payment
|
Professional record
- NPI
- 1750649471
- Licence
- CA A124321California A124321: Current · expires 2028-09-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207QA0401X (207QA0401X); Federal specialty code 2083A0300X (2083A0300X)
- Mailing address
- 1530 the Alameda Ste 301, San Jose, CA, 95126
- NPI first listed
- 2012-05-01
- NPI last updated
- 2025-03-17
- NPI record certified
- 2025-03-17
This is when the NPI record was last certified, not a medical board exam.